The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold $3 billion of Amazon… it’s why Nvidia’s CEO just sold $713 million... and it’s why Zuckerberg just sold $1.3 billion in Meta stock. The financial establishment doesn’t want you to know about this… but a controversial new documentary just pulled back the curtain and exposed what’s really going on. It’s called The Final Frontier.

Including the name of the #1 company to buy.

Robert Michael Herrman net worth and biography

Robert Herrman Biography and Net Worth

General Counsel of PetIQ

Mr. Herrman joined PetIQ as General Counsel in 2019 and currently serves as Executive Vice President, General Counsel and Corporate Secretary. He has practiced law for more than 23 years within the life sciences industry. Prior to joining PetIQ, he spent 16 years at Boehringer Ingelheim with 12 years in its Animal Health business. Since Mr. Herrman joined Boehringer Ingelheim's Animal Health business in 2007, it grew from the 10th largest global biological and pharmaceutical animal health company to the second largest in the world in 2017. Mr. Herrman has been a key contributor to numerous mergers, acquisitions and divestiture activities, which were transformative to its Animal Health business. Mr. Herrman served in leadership roles for the acquisition of a substantial portion of the Fort Dodge® Animal Health assets from Pfizer®, Inc./Zoetis®, Inc., more than doubling the size of the Animal Health business in 2009 and the acquisition of Merial®, Inc. from Sanofi in 2017. He earned a bachelor’s degree from the University of Connecticut, as well as a master’s degree from S.I. Newhouse School of Public Communication and a law degree from Syracuse University College of Law. Prior to that, Mr. Herrman served in the United States Army.

What is Robert Michael Herrman's net worth?: The estimated net worth of Robert Michael Herrman is at least $569,536.32 as of May 10th, 2021. Mr. Herrman owns 18,384 shares of PetIQ stock worth more than $569,536 as of November 17th. This net worth estimate does not reflect any other investments that Mr. Herrman may own. Learn More about Robert Michael Herrman's net worth.
How do I contact Robert Michael Herrman?: The corporate mailing address for Mr. Herrman and other PetIQ executives is 923 S. Bridgeway Pl., EAGLE ID, 83616. PetIQ can also be reached via phone at (208) 939-8900 and via email at [email protected]. Learn More on Robert Michael Herrman's contact information.
Has Robert Michael Herrman been buying or selling shares of PetIQ?: Robert Michael Herrman has not been actively trading shares of PetIQ during the past quarter. Most recently, on Tuesday, December 14th, Robert Michael Herrman bought 2,333 shares of PetIQ stock. The stock was acquired at an average cost of $21.51 per share, with a total value of $50,182.83. Learn More on Robert Michael Herrman's trading history.
Who are PetIQ's active insiders?: PetIQ's insider roster includes McCord Christensen (CEO), Robert Herrman (General Counsel), Ronald Kennedy (Director), John Newland (CFO), Susan Sholtis (President), and Michael Smith (EVP). Learn More on PetIQ's active insiders.
Are insiders buying or selling shares of PetIQ?: In the last year, insiders at the sold shares 1 times. They sold a total of 12,117 shares worth more than $268,876.23. The most recent insider tranaction occured on June, 12th when Director Scott Huff sold 12,117 shares worth more than $268,876.23. Insiders at PetIQ own 9.6% of the company. Learn More about insider trades at PetIQ.
Information on this page was last updated on 6/12/2024.

Robert Michael Herrman Insider Trading History at PetIQ

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/14/2021	Buy	2,333	$21.51	$50,182.83
5/10/2021	Sell	19,324	$42.25	$816,439.00	18,384
3/15/2021	Sell	16,119	$36.25	$584,313.75	17,123
3/11/2021	Sell	15,655	$36.25	$567,493.75	17,123
3/13/2020	Buy	1,004	$19.85	$19,929.40	676

Robert Michael Herrman Buying and Selling Activity at PetIQ

PetIQ Company Overview

PetIQ, Inc. operates as a pet medication and wellness company in the United States and internationally. It operates in two segments, Products and Services. The company offers Rx pet medications, which sells flea and tick control, heartworm preventatives, arthritis, thyroid, diabetes and pain treatments, antibiotics, and other specialty medications; and develops and manufactures its own proprietary value-branded products, as well as third-party branded products for dogs and cats. It also provides OTC medications and supplies primarily within the flea and tick control, dog dewormers, and behavior management categories of the health and wellness industry in various forms, such as spot on (topical) treatments, chewables, oral tablets, and collars. In addition, the company offers health and wellness products that include dog and cat treats, oral health solutions, stain and odor treatments, and pet nutritional supplements under the PetArmor®, Rocco & Roxie®, VetIQ®, Minties® and Sentry® brands. It provides its products primarily under the PetIQ, PetArmor, VIP Petcare, VetIQ PetCare, VetIQ, Capstar, Advecta, SENTRY, Sergeants, PurLuv, Rocco & Roxie, Minties, Heart Shield Plus, and TruProfen brand names. In addition, the company operates veterinarian service platform through community clinics, pop-up locations, wellness centers, and permanent locations that offer cost effective and convenient veterinary wellness services, including diagnostic tests, vaccinations, prescription medications, microchipping, grooming and hygiene, and wellness checks; and provides veterinary care services. It operates through veterinarian, retail, and e-commerce channels. PetIQ, Inc. was founded in 2010 and is headquartered in Eagle, Idaho.

Today's Range

Now: $30.98

$30.98

50 Day Range

MA: $30.87

$30.64

$30.99

2 Week Range

Now: $30.98

$15.09

$31.06

Volume

N/A

Average Volume

480,624 shs

Market Capitalization

$925.99 million

P/E Ratio

79.44

Dividend Yield

N/A

Beta

1.73

Financial Prophecy

From Porter & Company | Ad